Formycon reports audited annual results for the financial year 2023 – Looking back on a successful operative year and exceeded guidance marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
Formycon, a Germany-based biosimilar manufacturer, shared that its revenues for 2023 were 83% higher than in 2022, reaching a total of €77.7 million, according to its annual earnings report.
EQS-News: Formycon AG / Key word: Preliminary Results/Forecast
Convincing overall performance - Formycon reports preliminary results for the financial year 2023 and exceeds.
EQS-News: Formycon AG / Key word(s): Preliminary Results/ForecastConvincing overall performance - Formycon reports preliminary results for the financial year 2023 and exceeds forecast 12.04.2024 / 22:15 CET/CESTThe issuer is solely responsible for the content of this announcement.Press release // 12 April 2024 .